Next Article in Journal
Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer
Next Article in Special Issue
Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
Previous Article in Journal
Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
Previous Article in Special Issue
Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis

INSERM U1068, CNRS UMR7258, Aix-Marseille Université UM105, Institute Paoli-Calmettes, CRCM—Cancer Research Center of Marseille, U1068 Marseille, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1996; https://doi.org/10.3390/cancers12071996
Submission received: 28 May 2020 / Revised: 17 July 2020 / Accepted: 19 July 2020 / Published: 21 July 2020
(This article belongs to the Special Issue The Role of Src Kinase Family in Cancer)

Abstract

Protein tyrosine kinases have been recognized as important actors of cell transformation and cancer progression, since their discovery as products of viral oncogenes. SRC-family kinases (SFKs) play crucial roles in normal hematopoiesis. Not surprisingly, they are hyperactivated and are essential for membrane receptor downstream signaling in hematological malignancies such as acute myeloid leukemia (AML) and mastocytosis. The precise roles of SFKs are difficult to delineate due to the number of substrates, the functional redundancy among members, and the use of tools that are not selective. Yet, a large num ber of studies have accumulated evidence to support that SFKs are rational therapeutic targets in AML and mastocytosis. These two pathologies are regulated by two related receptor tyrosine kinases, which are well known in the field of hematology: FLT3 and KIT. FLT3 is one of the most frequently mutated genes in AML, while KIT oncogenic mutations occur in 80–90% of mastocytosis. Studies on oncogenic FLT3 and KIT signaling have shed light on specific roles for members of the SFK family. This review highlights the central roles of SFKs in AML and mastocytosis, and their interconnection with FLT3 and KIT oncoproteins.
Keywords: protein kinase; SFK; FLT3; KIT; AML; mastocytosis; kinase inhibitor protein kinase; SFK; FLT3; KIT; AML; mastocytosis; kinase inhibitor

Share and Cite

MDPI and ACS Style

Voisset, E.; Brenet, F.; Lopez, S.; de Sepulveda, P. SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. Cancers 2020, 12, 1996. https://doi.org/10.3390/cancers12071996

AMA Style

Voisset E, Brenet F, Lopez S, de Sepulveda P. SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. Cancers. 2020; 12(7):1996. https://doi.org/10.3390/cancers12071996

Chicago/Turabian Style

Voisset, Edwige, Fabienne Brenet, Sophie Lopez, and Paulo de Sepulveda. 2020. "SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis" Cancers 12, no. 7: 1996. https://doi.org/10.3390/cancers12071996

APA Style

Voisset, E., Brenet, F., Lopez, S., & de Sepulveda, P. (2020). SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. Cancers, 12(7), 1996. https://doi.org/10.3390/cancers12071996

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop